NCT02935361 2026-01-29
Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
University of Southern California
Phase 1/2 Active not recruiting
Clinical Trials
5 trialsNCT03206047 2025-03-13
Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT03308396 2022-02-17
Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer
Big Ten Cancer Research Consortium
Phase 1/2 Active not recruiting
NCT03576963 2021-04-05
Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer
University of Southern California
Phase 1/2 Withdrawn
NCT01896856 2020-10-06
Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed